Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-01-03 @ 9:31 PM
Study NCT ID:
NCT00905034
Status:
COMPLETED
Last Update Posted:
2015-06-29
First Post:
2009-05-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Leukemia, Lymphocytic, Acute | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Acute lymphoblastic leukemia | View |
| None | ALL | View |
| None | Leukemia | View |
| None | Methotrexate | View |
| None | Vincristine | View |
| None | PEG-l-asparaginase | View |
| None | PEG asparaginase | View |
| None | Pegaspargase | View |
| None | Oncaspar | View |
| None | Polyethylene Glycol Conjugated Lasparaginase-H | View |
| None | Dexamethasone | View |
| None | Decadron | View |
| None | Rituximab | View |
| None | Rituxan | View |